EOLS on Nasdaq

Evolus, Inc.

American pharmaceutical preparations company based in Newport Beach. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Ironwood Pharmaceuticals, RIGEL PHARMACEUTICALS INC or Xeris Biopharma Holdings, Inc., or pick any stock.

  • TickerEOLS on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersNewport Beach, United States2
  • Incorporated inDE3
  • Business address520 Newport Center Drive, Suite 1200, Newport Beach, Ca 926603
  • Filer categoryAccelerated filer3
  • Legal formCorporation2
  • LEI549300VYQRYBQOT8V4192
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o REGISTERED AGENT SOLUTIONS, INC., 838 WALKER ROAD SUITE 21-2, 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 52398912

See how the biggest companies compare on our leaderboards

You should carefully consider these risks, as well as the additional risks described in other documents we file with the U.S. Securities and Exchange Commission (“SEC”) in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

66.3%Gross margin5
-11.0%Operating margin5
-17.4%Net margin5
11.6%Revenue growth, 20255
-$45.7MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 99% of the revenue Evolus, Inc. broke down this way in fiscal 2025.

  1. Product$295.0M599%up 12% from 2024
  2. Service$2.2M51%up 13% from 2024
Products and services by year
Products and services202320242025
Product$199.7M$264.3M$295.0M
Service$2.4M$2.0M$2.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue31¢$100.1M
  • Selling, general and admin69¢$220.8M
  • Income tax0¢$677.0K

Out of $297.2M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$297.2M in 2025+751% since 2019
0$100.0M$200.0M$300.0M2019: $34.9M$34.9M20192020: $56.5M$56.5M2020+62%2021: $99.7M$99.7M2021+76%2022: $148.6M$148.6M2022+49%2023: $202.1M$202.1M2023+36%2024: $266.3M$266.3M2024+32%2025: $297.2M$297.2M2025+12%
Gross profit1095$197.1M in 2025+632% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $26.9M$26.9M20192022: $89.8M$89.8M2022+234%2023: $137.6M$137.6M2023+53%2024: $182.3M$182.3M2024+33%2025: $197.1M$197.1M2025+8%
Operating income67895-$32.7M in 2025−67% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$98.9M-$98.9M20192020: -$153.1M-$153.1M2020+55%2021: -$44.4M-$44.4M2021−71%2022: -$65.3M-$65.3M2022+47%2023: -$49.2M-$49.2M2023−25%2024: -$34.4M-$34.4M2024−30%2025: -$32.7M-$32.7M2025−5%
Net income67895-$51.6M in 2025−43% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$90.0M-$90.0M20192020: -$163.0M-$163.0M2020+81%2021: -$46.8M-$46.8M2021−71%2022: -$74.4M-$74.4M2022+59%2023: -$61.7M-$61.7M2023−17%2024: -$50.4M-$50.4M2024−18%2025: -$51.6M-$51.6M2025+2%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenues$297.2M$266.3M$202.1M
Cost of goods sold$100.1M$84.0M$64.5M
Gross profit$197.1M$182.3M$137.6M
Selling, general and administrative$220.8M$198.0M$164.9M
Research and development$9.6M$9.2M$6.6M
In-process research and development$0$0$8.9M
Revaluation of contingent royalty obligation payable to Evolus Founders-$6.4M$7.2M$4.3M
Depreciation and amortization$4.3M$2.3M$2.2M
Restructuring costs$1.4M$0$0
Total operating expenses$229.8M$216.7M$186.8M
Loss from operations-$32.7M-$34.4M-$49.2M
Interest income$1.9M$3.3M$860.0K
Interest expense-$19.7M-$18.7M-$13.8M
Other income (expense), net-$539.0K$127.0K$696.0K
Loss before income taxes-$51.0M-$49.8M-$61.5M
Income tax expense-$677.0K-$664.0K-$176.0K
Net loss-$51.6M-$50.4M-$61.7M
Currency translation adjustment$749.0K-$478.0K-$90.0K
Comprehensive loss-$50.9M-$50.9M-$61.8M
Net loss per share, basic (in dollars per share)-$0.80-$0.81-$1.08
Net loss per share, diluted (in dollars per share)-$0.80-$0.81-$1.08
Weighted-average shares outstanding used to compute basic net loss per share (in shares)64.5M shares62.0M shares56.9M shares
Weighted-average shares outstanding used to compute diluted net loss per share (in shares)64.5M shares62.0M shares56.9M shares

Compare Evolus, Inc. with another company

Leadership

Who has led Evolus, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Sandra Beaver2022–2025
  2. Tatjana Mitchell2025–now

Chief operating officer

  1. J. Christopher Marmo2018
20202025
Board members and other officers (17)

Timeline

  1. Nov 9, 2012Founded Evolus, Inc. is founded2

Filings

291 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 132 insider forms, 41 large holders, 50 other. The latest 20:

  1. Sep 4, 20264 EDGAR
  2. Sep 2, 2026144 EDGAR
  3. Aug 31, 2026SCHEDULE 13G EDGAR
  4. Aug 5, 202610-Q EDGAR
  5. Aug 5, 20268-K EDGAR
  6. Aug 4, 20268-K EDGAR
  7. Jul 8, 20268-K EDGAR
  8. Jun 12, 2026EFFECT EDGAR
  9. Jun 12, 20268-K EDGAR
  10. Jun 10, 2026CORRESP EDGAR
  11. Jun 10, 2026UPLOAD EDGAR
  12. Jun 5, 2026S-3 EDGAR
  13. May 4, 202610-Q EDGAR
  14. May 4, 20268-K EDGAR
  15. Apr 29, 2026DEFA14A EDGAR
  16. Apr 29, 2026DEF 14A EDGAR
  17. Apr 29, 2026ARS EDGAR
  18. Mar 26, 2026SCHEDULE 13G/A EDGAR
  19. Mar 20, 20264 EDGAR
  20. Mar 20, 20264 EDGAR

The 291 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

81 open-market trades by officers, directors and large owners since October 2021: 9 buys and 72 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 2, 2026MOATAZEDI DAVIDSee RemarksSale105,108$9.04$950.2KForm 4
Mar 20, 2026Avelar RuiSee RemarksSale3,119$4.75$14.8KForm 4
Mar 20, 2026MOATAZEDI DAVIDSee RemarksSale13,669$4.75$64.9KForm 4
Mar 17, 2026MOATAZEDI DAVIDSee RemarksSale116,720$4.89$570.8KForm 4
Mar 17, 2026Avelar RuiSee RemarksSale29,996$4.89$146.7KForm 4
Dec 22, 2025MOATAZEDI DAVIDSee RemarksSale10,539$7.15$75.4KForm 4
Dec 22, 2025Avelar RuiSee RemarksSale2,261$7.15$16.2KForm 4
Aug 22, 2025Yamagishi-Dressler TomokoChief Marketing OfficerSale5,722$7.51$43.0KForm 4
Aug 15, 2025Stewart BradyDirectorBuy30,000$6.82$204.6KForm 4
Jun 16, 2025MOATAZEDI DAVIDSee RemarksSale16,582$9.89$164.0KForm 4
Jun 13, 2025MOATAZEDI DAVIDSee RemarksSale111,323$10.05$1.1MForm 4
Jun 9, 2025White Albert G IIIDirectorBuy20,000$9.45$189.0KForm 4
May 13, 2025Beaver SandraChief Financial OfficerSale6,494$10.02$65.1KForm 4
May 12, 2025Avelar RuiSee RemarksSale3,385$9.87$33.4KForm 4
May 12, 2025MOATAZEDI DAVIDSee RemarksSale15,787$9.87$155.8KForm 4
Mar 27, 2025MOATAZEDI DAVIDSee RemarksSale6,251$12.40$77.5KForm 4
Mar 18, 2025Avelar RuiSee RemarksSale27,904$13.26$370.0KForm 4
Mar 18, 2025Beaver SandraChief Financial OfficerSale8,996$13.26$119.3KForm 4
Mar 18, 2025Yamagishi-Dressler TomokoChief Marketing OfficerSale4,536$13.26$60.1KForm 4
Mar 18, 2025MOATAZEDI DAVIDSee RemarksSale103,376$13.26$1.4MForm 4

All 81 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC11,204,042$77.8M2.4%+4,827,185
BlackRock, Inc.4,840,828$33.6M0.0%+550,445
Braidwell LP3,155,209$21.9M0.8%+50,000
Frazier Life Sciences Management, L.P.2,630,665$18.3M0.4%No change
Perceptive Advisors LLC2,459,285$17.1M0.3%+1,172,423
Vanguard Capital Management LLC2,362,893$16.4M0.0%−107,515
Assenagon Asset Management S.A.1,816,360$12.6M0.0%+1,218,215
Millennium Management LLC1,787,929$12.4M0.0%+326,770
State Street Corp1,697,294$11.8M0.0%+376,504
Geode Capital Management, LLC1,608,394$11.2M0.0%+227,056
Stonepine Capital Management, LLC1,590,162$11.0M8.4%−168,929
Point72 Asset Management, L.P.1,508,518$10.5M0.0%New
Pinnacle Associates Ltd1,487,264$10.3M0.1%+328,369
Armistice Capital, LLC1,436,000$10.0M0.3%+40,000
Rice Hall James & Associates, LLC1,289,888$9.0M0.4%+35,069
AWH Capital, L.P.1,250,000$8.7M3.0%+625,000
Goldman Sachs Group Inc1,219,419$8.5M0.0%+133,021
Soleus Capital Management, L.P.822,428$5.7M0.2%−1,422,932
Soviero Asset Management, LP770,000$5.3M2.6%+89,627
UBS Group AG752,679$5.2M0.0%−202
Vanguard Portfolio Management LLC545,702$3.8M0.0%+68,625
Charles Schwab Investment Management Inc530,843$3.7M0.0%+15,327
Citadel Advisors LLC506,354$3.5M0.0%−190,275
Northern Trust Corp497,018$3.4M0.0%+24,675
Vanguard Fiduciary Trust Co456,183$3.2M0.0%+31,525

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46